3rd Local Primary Care Unit (TOMY), Division of Endocrinology and Metabolism and Diabetes Center, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
First Department of Internal Medicine, Division of Endocrinology and Metabolism and Diabetes Center, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
Indian J Pharmacol. 2020 Jan-Feb;52(1):44-48. doi: 10.4103/ijp.IJP_80_19. Epub 2020 Mar 11.
We aimed to explore whether fasting insulin levels correlate with the risk of hypoglycemia in people with Type 2 diabetes (T2D) receiving sulfonylureas (SUs).
Our study included 58 individuals with T2D who had been on treatment with SUs, but not insulin, for more than 2 years. Confirmed hypoglycemic episodes during the past year were self-reported by the patients, and a potential relationship of hypoglycemic event frequency with fasting insulin levels was investigated.
Fasting insulin concentrations were found to have a low positive and statistically significant correlation with the number of cases of mild hypoglycemia per year ( = 0.279/P = 0.034) and a moderately positive and statistically significant correlation with the number of severe hypoglycemic events per month ( = 0.349/P = 0.007) and per year ( = 0.39/P = 0.002).
Our results suggest that fasting insulin levels might be a predictor of the risk of hypoglycemia in people with T2D on treatment with SUs.
我们旨在探讨 2 型糖尿病（T2D）患者接受磺酰脲类药物（SUs）治疗时，空腹胰岛素水平与低血糖风险是否相关。
我们的研究纳入了 58 名 T2D 患者，他们使用 SUs 治疗超过 2 年，但未使用胰岛素。过去一年中的低血糖发作由患者自行报告，并调查低血糖事件频率与空腹胰岛素水平之间的潜在关系。
空腹胰岛素浓度与每年轻度低血糖发作次数呈低度正相关（= 0.279，P = 0.034），与每月重度低血糖发作次数（= 0.349，P = 0.007）和每年重度低血糖发作次数（= 0.39，P = 0.002）呈中度正相关。
我们的研究结果表明，空腹胰岛素水平可能是接受 SUs 治疗的 T2D 患者低血糖风险的预测指标。
